News
  Date Title View
Jul 3, 2017
BURLINGTON, Mass., July 03, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will hold an Investor and Analyst Day on Monday, July 10, 2017. Flexion executives will discuss plans for commercializing Zilretta™ (FX006), the company's lead investigational product candidate for the tr...
Jun 28, 2017
BURLINGTON, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has further strengthened its leadership team with the appointment of Mark Levine as Senior Vice President, General Counsel and Secretary. Mr. Levine joins the company's impressive roster of industry veterans, and...
Jun 23, 2017
BURLINGTON, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been recognized as one of the The Boston Business Journal's "Best Places to Work." Flexion ranked 5th in the medium business category (100 to 249 employees) and was presented with the awar...
Jun 10, 2017
BURLINGTON, Mass., June 10, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present the full results from a Phase 2 study which found its lead investigational product candidate Zilretta (also known as FX006) was associated with reduced blood glucose (BG) elevation compared with immediate release triamcinol...
May 22, 2017
Findings suggest Zilretta could potentially provide a cost-effective treatment option for patients with osteoarthritis of the knee BURLINGTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the findings from a new health economics analysis of Zilr...
May 18, 2017
BURLINGTON, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the upcoming presentation of the full results from a Phase 2 clinical trial of its lead investigational product candidate, Zilretta™ (FX006), in patients with Type 2 diabetes and osteoarthritis (OA) of the knee. The...
May 4, 2017
Capital infusion of approximately $201 million (gross proceeds) through recent offering of convertible senior notes expected to provide cash runway into 2019New patents issued in U.S. further strengthen intellectual property (IP) estate for Zilretta™ (FX006), our lead product candidateCl...
May 1, 2017
BURLINGTON, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 2:1...
Apr 28, 2017
In an analysis of pooled Phase 2/3 data, ZilrettaTM (FX006) demonstrated clinically meaningful pain relief and functional improvement in patients with osteoarthritisA separate Phase 2 study shows prolonged synovial localization and diminished systemic exposure of corticosteroid with Zilretta compared...
Apr 26, 2017
BURLINGTON, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of $175.0 million aggregate principal amount of 3.375% convertible senior notes due 2024 (the "Notes") in a private placement to qualified institutional bu...
FirstPrevious
3
... NextLast
= add release to Briefcase